[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 389
Citations 0
Comment & Response
April 11, 2017

Zoledronic Acid Dosing Interval for Metastatic Cancer

Author Affiliations
  • 1Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan
  • 2Teikyo University Chiba Medical Center, Chiba, Japan
JAMA. 2017;317(14):1477. doi:10.1001/jama.2017.2558

To the Editor Dr Himelstein and colleagues1 found that the use of zoledronic acid every 12 weeks compared with the standard dosing interval of 4 weeks did not result in an increased risk of skeletal events over 2 years in patients with bone metastases. The randomized, open-label clinical trial included 855 patients with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma, broadening the potential applicability of the findings. Although the authors concluded that this longer interval may be an acceptable treatment option, we would like to raise a concern about applying the study results to patients with multiple myeloma.